Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
You may also be interested in...
Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.
The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.